Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
News|Articles|April 15, 2026
International Pompe Day 2026: Top News and Expert Insights
Author(s)Noah Stansfield
In observance of International Pompe Day, held annually on April 15, catch up on the past year’s news and expert insights related to this rare disease.
Advertisement
Advertisement
According to the National Organization for Rare Disorders, Pompe disease occurs in approximately 1 in 40,000 births in the United States and the Netherlands; however, in some populations, the incidence is substantially higher.1 Over the past year, NeurologyLive® has covered news and clinical trial data updates related to the various therapies currently in development for Pompe disease and conducted interviews with experts to discern the potential for new research and treatments to affect the care paradigm.
Related to this article
The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.
New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.
Here's some of what is coming soon to NeurologyLive® this week.
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent advances in gene therapies.
A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.
At a NeurologyLive and Targeted Oncology Clinical Forum in Houston, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how incidental diagnosis and limited awareness of systemic therapy continue to delay care for patients with NF1-associated plexiform neurofibromas.
Advertisement
Advertisement